HONG KONG, Oct. 30, 2026 /PRNewswire/ -- The Mother of All Rivalries lived up to its billing as Pakistan defeated arch-rivals India by 4 wickets in Match 7 of the Hong Kong Sixes 2026. Pakistan captain Abbas Afridi won the toss and elected to bowl, restricting India to 88/5 in 6 overs, despite Shashank Singh's explosive 40 off just 11 balls. In reply, Pakistan chased down the target of 89 in just 3.5 overs, courtesy of Khawaja Nafay's unbeaten 41 off 12 balls and Abbas' blistering 35 off 8 deliveries.
India got off to a steady start, scoring 11 runs in the opening over before Muhammad Shahzad dismissed Rahul Tripathi for 9 off 5 balls. Shashank Singh counterattacked immediately, smashing 16 runs off 3 deliveries. While Abbas Afridi conceded just 11 runs in the 3rd over, Shashank continued his assault with 24 runs in the 4th, including 3 sixes and a boundary. Nitish Rana, who scored 19 off 14 balls, was retired out in the 5th over, but Abdul Samad struck twice in consecutive deliveries, dismissing Rahul Tewatia and captain Krunal Pandya for golden ducks. Ahmed Daniyal then removed Shashank off the first ball of the final over as India finished at 88/5, with T. Natarajan adding 12 runs.
Pakistan began their chase aggressively, with Abbas smashing 5 consecutive sixes off Krunal Pandya to power a 31-run opening over. The onslaught continued as Pakistan plundered another 28 runs off T. Natarajan's over. Abbas was eventually dismissed by Shashank for 35 off 8 balls, but the breakthrough came too late as Pakistan were already cruising at 73/1. Nafay remained unbeaten on 41, featuring 2 fours and 5 sixes, while Irfan Khan struck the winning runs to seal Pakistan's first victory of the 2026 edition.
If India beats UAE, the points of all the 3 teams from Group C will be tied and the team who has hit the most sixes will qualify for the Cup Category.
Current Sixes Tally of Group C
Pakistan: 23 (2 Matches)
UAE: 12 (1 Match)
India: 7 (1 Match)
Match Summary
India 88/5 (6 overs)
Shashank Singh 40(11)
Abdul Samad 1/10 (2 overs)
Pakistan 91/2 (3.5 overs)
Khawaja Nafay 41(12)
Shashank Singh 1/14 (1 over)
Result: Pakistan beat India by 4 wickets
Player of the Match: Abbas Afridi 35(8)
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Pakistan Dominate India in a High-Voltage Hong Kong Sixes Showdown
BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.
A Three-Year Partnership Built on a Trusted R&D Model
Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.
At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.
In-Depth Discussions Explore New Collaboration Opportunities
During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.
Laboratory Tour
Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
